A statistically significant reduction in the composite endpoint was seen for patients who received the abciximab bolus plus infusion vs those who received a placebo (P = 0.008). This benefit was maintained at 6 months and at 3 years. Also noteworthy in this trial was the increased number of bleeding complications experienced by patients who received the abciximab bolus plus infusion regimen. Heparin dosing was quite liberal in this study, and infusions continued for at least 12 hours (1) .
The 2792 patients included in the EPILOG study were undergoing elective or urgent revascularization procedures. Patients could be at all risk levels, but those with UA or acute MI were excluded. Heparin dosing was adjusted for weight, which was not done in the EPIC trial. The primary endpoints for this study were death from any cause, MI or reinfarction, or severe MI requiring urgent CABG or repeat revascularization within 30 days.
After the first interim analysis, statistical significance was reached between the responses of the abciximab plus low-dose heparin group vs the placebo group, and patient enrollment was therefore terminated. Patients in the placebo group had a higher rate of endpoint events (P < 0.001). The incidence of bleeding was not higher for patients receiving abciximab plus heparin therapy (2) .
The CAPTURE study was designed to evaluate patients with refractory UA. The primary endpoints were defined as death, MI, or the need for an urgent procedure to treat a recurrent ischemic episode. In contrast to the previously described abciximab studies, infusions were started 18 to 24 hours before the start of the scheduled angioplasty procedure and were continued for 1 hour afterwards.
The study was discontinued prematurely, after 1265 patients were enrolled. At the third interim analysis, a statistically significant higher percentage of patients in the placebo group had reached the primary endpoint compared with those in the abciximab group (P = 0.0064) (3).
The final abciximab study is the EPISTENT trial. Previous work had established that stenting was superior to balloon angioplasty because stenting reduced the need for repeat revascularization. Despite this technological advancement, the rates of death and MI had not decreased proportionately. The other EPILOG 0.25 mg/kg bolus, then 0.125 µg/kg/min 325 mg aspirin (2 hours prior) plus 100 units/kg Interim analysis at 30 days revealed 5.2% incidence in com-Decreased bleeding rate with (2/95-12/95) (maximum, 10 µg/min) infusion for 12 hours bolus, then weight-adjusted heparin for low-posite endpoints in low-dose heparin group and 5.4% with adjusted-dose heparin arm vs heparin placebo dose and traditional arms (ACT 200-300 seconds) standard-dose heparin vs 11.7% with placebo (P < 0.001).
CAPTURE 0.25 mg/kg bolus, then 10 µg/kg/min infusion 50 mg aspirin (minimum) plus 100 units/kg Study stopped after interim analysis of data showing Major bleeding complications (5/93-12/95) 18-24 hours before angioplasty and 1 hour heparin (10,000 units maximum), then 10.8% had primary endpoint in treatment group vs in 3.8% of patients after completion vs heparin placebo heparin infusion (ACT 300 seconds) before 16.4% with placebo (P = 0.0064); at 30 days it was randomization until 1 hour after angioplasty 11.3% vs 15.9% for placebo (P = 0.012).
EPISTENT 0.25 mg/kg bolus, then 0.125 µg/kg/min 325 mg aspirin (2 hours prior) plus weight-10.8% incidence in composite endpoints for stent plus Bleeding rates similar among (7/96-9/97) (maximum, 10 µg/min) infusion for 12 hours adjusted heparin with or without ticlopidine placebo vs 5.3% for stent plus abciximab (P < 0.001) and groups vs heparin placebo 6.9% for angioplasty plus abciximab (P = 0.007).
Eptifibatide
IMPACT 90 µg/kg bolus, then 1 µg/kg/min infusion 325 mg aspirin plus 10,000 units heparin bolus, 4.1% incidence in primary composite endpoint at 30 days Major bleeding incidence every 4 hours vs 90 µg/kg bolus, then then adjusted-dose heparin to ACT > 300 seconds for 12-hour group vs 9.6% for 4-hour group vs 12.2% for similar among all groups 1 µg/kg/min infusion every 12 hours (started after vascular access established) placebo (insignificant).
IMPACT-II 135 µg/kg bolus, then 0.5 µg/kg/min or 325 mg aspirin plus 100 units/kg heparin bolus, Composite endpoint reached by 11.4% in placebo group vs Major bleeding incidence (11/93-11/94) 0.75 µg/kg/min for 20-24 hours vs then infusion (ACT 300-350 seconds) 9.9% in high-dose drug arm vs 9.2% in low-dose drug arm similar among all groups heparin placebo at 30 days (insignificant); rates maintained at 6 months.
PURSUIT 180 µg/kg bolus, then 1.3 µg/kg/min Aspirin at discretion of investigator Composite endpoint reached by 15.7% in placebo group Increased risk of bleeding (11/95-1/97) infusion vs 180 µg/kg bolus, then (could give ticlopidine) with or without heparin (± heparin) vs 14.2% in high-dose drug group at 30 days and a greater need for 2.0 µg/kg/min infusion for 72-96 hours (P = 0.04). Of patients requiring revascularization within blood transfusions 72 hours (59.9% vs 59.0%): 16.7% placebo vs 11.6% drug (P = 0.01). (1/95-12/95) for 36 hours vs heparin placebo (10,000 units maximum), then infusion (ACT vs 10.3% for placebo (P = 0.16). thrombocytopenia or major 300-400 seconds) within 12 hours before bleeding with tirofiban procedure. Discontinued at end of procedure; sheath removed when ACT < 180 seconds * Composite endpoints for studies were generally identified as death from any cause, myocardial infarction, or refractory ischemia requiring intervention. Please refer to the specific study for actual study design. ACT indicates activated coagulation time; APTT, activated partial thromboplastin time.
Tirofiban
abciximab trials involved balloon angioplasty techniques. EPISTENT enrolled 2399 patients who were scheduled to receive elective or urgent revascularization. This trial compared the use of stents with a heparin placebo, stents with abciximab, and balloon angioplasty with abciximab. The primary endpoint criteria were met if patients experienced death, had an MI or reinfarction, or were required to undergo urgent revascularization or CABG surgery within 30 days.
Patients assigned to the stent plus placebo group reached the primary endpoint at a higher rate compared with those in either treatment group (stent plus abciximab, P < 0.001; angioplasty plus abciximab, P = 0.007) (4).
EPTIFIBATIDE TRIALS
Three trials were conducted involving the agent eptifibatide, a synthetic cyclic heptapeptide that competitively binds to the arginine-glycine-aspartate recognition site. They were Integrelin to Minimize Platelet Aggregation and Prevent Coronary Thrombosis (IMPACT), Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II (IMPACT-II), and Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT).
IMPACT was a phase II clinical trial enrolling 150 patients who were scheduled for elective balloon angioplasty or directional coronary atherectomy. Patients received either placebo or a bolus of eptifibatide followed by a 4-or 12-hour infusion of the study drug. The primary efficacy endpoint was the occurrence of death, MI, or urgent coronary intervention. Results of the study were not statistically significant, probably due to study design and a small sample size (5).
IMPACT-II was a phase III clinical trial that enrolled 4010 patients. Patients met criteria for enrollment if they had scheduled an elective, urgent, or emergency coronary intervention. Patients were randomized to receive either a placebo regimen or a bolus of eptifibatide with 1 of 2 treatment dose infusions. Infusions continued for 20 to 24 hours after the procedure was completed. Primary endpoints were defined as death, MI, or unanticipated revascularization, including stent placement, for management of abrupt closure or recurrent ischemia within the first 30 days.
The composite primary endpoint occurred at a similar rate for all of the treatment groups. The higher-dose regimen did not improve clinical efficacy compared with the lower-dose arm (6) .
The final eptifibatide study is the PURSUIT trial. Patients who presented with symptoms of UA or a non-Q wave MI were recruited from 28 countries. They were randomized to receive 1 of 3 regimens: a placebo bolus followed by a placebo infusion or a bolus dose of eptifibatide followed by 1 of 2 eptifibatide infusions. Infusions continued for up to 72 hours, unless an intervention was performed near the end of the 72-hour period. In such a case, the infusion could continue for an additional 24 hours, or 96 hours total. Catheterization or other revascularization procedures could be performed at the treating physician's discretion. Primary endpoints were death or nonfatal MI at 30 days.
There was a statistically significant difference between the groups in the frequency of the development of the composite endpoint at 30 days. Those randomized to receive the placebo infusion had a higher incidence of death or nonfatal MI (P = 0.04). Noteworthy, however, was that the frequency of patients requiring revascularization within 72 hours was the same for all 3 groups. The median time for infusion of study drug was 72 hours (7).
TIROFIBAN TRIALS
There are 3 primary trials to discuss involving the agent tirofiban, a nonpeptide that mimics the geometric, stereotactic, and charge characteristics of the arginine-glycine-aspartate sequence and thus interferes with platelet aggregation. They are titled Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM), Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS), and Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE).
The PRISM study enrolled 3232 patients with ischemic symptoms of UA. Patients were randomized to receive either a placebo infusion or a loading dose of tirofiban plus a maintenance infusion for 47.5 hours. The primary endpoint was a composite of death, MI, or refractory ischemia at the end of the 48-hour infusion.
A decrease in the rate of occurrence of the composite endpoint in the tirofiban group was statistically significant at 48 hours (P = 0.01) but was not maintained at the 30-day mark. Angiography was performed in 62% of the cases within the first 30 days. While this study was designed for "medical management" of the patient, those treated as such were not discussed separately (8) .
The PRISM-PLUS trial involved 1915 patients with UA or non-Q wave MI. Unlike the PRISM trial, where patients were enrolled within 12 hours of when their chest pain began, patients were enrolled within 24 hours of the onset of symptoms. Two different tirofiban dosing regimens, one containing heparin therapy, were chosen to be compared with placebo. Primary endpoints were defined as a composite of death, new MI, refractory ischemia within 7 days, or rehospitalization for UA.
The rate of the development of the composite endpoint was statistically lower for patients randomized to the tirofiban plus heparin dosing arm. Sixty percent of patients required revascularization procedures subsequent to drug therapy with tirofiban (9) .
The RESTORE trial targeted patients who were to undergo coronary intervention within 72 hours of presenting with UA or an acute MI. A total of 2212 patients were randomized to receive either a bolus dose of tirofiban and then a constant infusion of tirofiban for 36 hours or placebo. Endpoints of the study were defined as death, MI, CABG surgery, or any revascularization procedure, including stent placement, within the first 30 days. Results of the study showed no statistically significant difference between the groups in the development of the primary endpoints (10).
SUMMARY
Many editorial reviews and supplemental analyses have been written since results of these important investigative trials were published. A thorough review of each study will provide readers with a foundation from which to critically evaluate such literature. Practitioners can put each study into the proper perspec-tive and ultimately make decisions about the use of these agents in their own clinical practices.
